During Lytic Infections, Herpes Simplex Virus Type 1 DNA is in Complexes with the Properties of Unstable Nucleosomes
Overview
Authors
Affiliations
The genomes of herpes simplex virus type 1 (HSV-1) are regularly chromatinized during latency such that their digestion with micrococcal nuclease (MCN) releases nucleosome-sized DNA fragments. In lytically infected cells, in contrast, MCN releases HSV-1 DNA in primarily heterogeneously sized fragments. Consistently, only a small percentage of this HSV-1 DNA coimmunoprecipitates with histones. Most current models propose that histones associate with HSV-1 DNA during lytic infections at low occupancy. However, histone modification or occupation is also proposed to regulate HSV-1 transcription. It remains unclear how the histones associated with a small percentage of HSV-1 DNA may regulate transcription globally. Moreover, the physical properties of the complexes containing histones and HSV-1 DNA are unknown. We evaluated the HSV-1 DNA-containing complexes at 5 h after (lytic) infection by biochemical fractionations. Nuclear HSV-1 DNA did not fractionate as protein-free HSV-1 DNA but as DNA in cellular nucleosomes. Moreover, MCN released HSV-1 DNA in complexes that fractionate as cellular mono- and dinucleosomes by centrifugation followed by sucrose gradients and size-exclusion chromatography. The HSV-1 DNA in such complexes was protected to heterogeneous sizes and was more accessible to MCN than DNA in most cellular chromatin. Using a modified MCN digestion to trap unstable digestion intermediates, HSV-1 DNA was quantitatively recovered in discrete mono- to polynucleosome sizes in complexes fractionating as cellular mono- to polynucleosomes. The HSV-1 DNAs in complexes fractionating as mono- to dinucleosomes were stabilized by cross-linking. Therefore, most HSV-1 DNA forms particularly unstable nucleosome-like complexes at 5 h of lytic infection.
The opportunities and challenges of epigenetic approaches to manage herpes simplex infections.
Saddoris S, Schang L Expert Rev Anti Infect Ther. 2024; 22(12):1123-1142.
PMID: 39466139 PMC: 11634640. DOI: 10.1080/14787210.2024.2420329.
Roberts A, Orr A, Iliev V, Orr L, McFarlane S, Yang Z bioRxiv. 2024; .
PMID: 39185184 PMC: 11343217. DOI: 10.1101/2024.08.15.608064.
Flores Cortes E, Saddoris S, Owens A, Gibeault R, Depledge D, Schang L J Virol. 2024; 98(4):e0201523.
PMID: 38451083 PMC: 11019955. DOI: 10.1128/jvi.02015-23.
Jennings M, Parks R Viruses. 2023; 15(1).
PMID: 36680201 PMC: 9863843. DOI: 10.3390/v15010161.
Aliabadi N, Jamalidoust M, Pouladfar G, Azarpira N, Ziyaeyan A, Ziyaeyan M Heliyon. 2022; 8(8):e10348.
PMID: 36090228 PMC: 9449773. DOI: 10.1016/j.heliyon.2022.e10348.